0On record
No trial on ClinicalTrials.gov lists this combination
We found no registered interventional trial on
ClinicalTrials.gov that administers CJC-1295, Ipamorelin and IGF-1 LR3 together. The individual
compounds may have trials of their own — those are listed below — but a
trial of one ingredient does not tell you what the mixture does.
That is not a claim the combination is harmful or useless. It means the
specific question has not been asked on the record.
The ingredients, separately
CJC-1295
Modified GRF (1-29) · DAC:GRF
One human trial ever registered, and it was stopped early. The registry does not say why.
Studied on its own
1
Registered trials
Ipamorelin
Growth hormone secretagogue
Both completed human trials studied bowel movement after surgery. Neither studied muscle, fat, or aging.
Studied on its own
2
Registered trials
IGF-1 LR3
Long R3 IGF-1 · LongR3
A modified IGF-1 analogue developed as a cell-culture reagent, not a medicine. Zero registered human trials of the analogue itself.
No registered trial
0
Registered trials
—Read this
Why combinations are studied separately
Two compounds given together can interact — in how they are absorbed, how long they last, or what they do at the same receptor. That is why regulators treat a fixed combination as its own product requiring its own trials. CagriSema is the example on this site of a combination developed and tested as one thing.